Loading...
Loading...
PRPO| Name | Value |
|---|---|
| Revenues | 4,441.0K |
| Cost of Revenue | 3,022.0K |
| Gross Profit | 1,419.0K |
| Operating Expense | 2,628.0K |
| Operating I/L | -1,209.0K |
| Other Income/Expense | -11.0K |
| Interest Income | 0.0K |
| Pretax | -1,220.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,220.0K |
Precipio, Inc. is a healthcare solutions company in the United States, specializing in diagnostic blood cancer testing services. The company offers a range of products and services including IV-Cell, HemeScreen genetic diagnostic panels, ICE-COLD PCR technology, and COVID-19 antibody tests. It generates revenue through the sale of its proprietary cell culture media, genetic diagnostic panels, ICE-COLD-PCR technology kits, and COVID-19 antibody tests. Additionally, Precipio, Inc. collaborates with academic institutions focused on cancer research, diagnostics, and treatment, further enhancing its product offerings and market presence.
